EMA Monitors Products from Japan to Avoid Radioactivity

The EMA is working with regulatory partners to monitor and evaluate the possibility of radioactive contamination of medicines manufactured in Japan.

The European Medicines Agency is working with its European and international regulatory partners to monitor and evaluate the possibility of radioactive contamination of medicines manufactured in Japan following the radiation leak from the Fukushima Daiichi nuclear power plant.

The exchange of information with the Japanese competent authorities, the Ministry of Health, Labour and Welfare (MHLW) and the Ministry for Agriculture, Forestry and Fisheries (MAFF), as well as with other regulatory partners around the globe, has reassured the Agency that the risk to public and animal health, if any, is very small.

The Agency is taking a precautionary approach that takes into account the measures put in place in the European Union for food and animal fe